Physician profile
Mrinal Joshi
NPI 1255731253
$3,000.33
in general payments reported to CMS, 2019-2025
25 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,501 · 2022: $863 · 2023: $449 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,285.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $240.99 | 2021-2023 | |
| Novo Nordisk INC | $215.63 | 2022-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $196.21 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $195.94 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $144.33 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $126.50 | 2025 | Spravato |
| Abbott Laboratories | $121.82 | 2022 | |
| Alkermes, INC. | $111.72 | 2022 | |
| Lilly USA, LLC | $48.35 | 2022-2023 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $42.74 | 2022 | |
| Almatica Pharma LLC | $26.15 | 2021 | |
| Corium, LLC | $24.21 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $23.48 | 2023 | Gardasil 9, Vaxelis, Pneumovax 23 |
| Astellas Pharma US INC | $23.38 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.58 | 2023 | |
| Nevro Corp. | $20.57 | 2023 | Senza |
| Pfizer INC. | $19.69 | 2023 | |
| Amarin Pharma, INC. | $19.23 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.97 | 2022 | |
| Neurocrine Biosciences, INC. | $18.74 | 2021 | |
| Intuitive Surgical, INC. | $16.73 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.33 | 2022 | |
| Currax Pharmaceuticals LLC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mrinal Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.